GlassScriptPhysician profile
Yara S Ramirez
NPI 1225418932
$5,210.37
in general payments reported to CMS, 2019-2025
43 companies · $711 in 2025
The $711 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $305 · 2021: $505 · 2022: $548 · 2023: $663 · 2024: $2,179 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054 · Education: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.63 |
| Education | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,500.00 | 2024 | |
| Abbvie INC. | $516.43 | 2020-2025 | |
| Novo Nordisk INC | $372.70 | 2022-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $363.57 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $362.60 | 2019-2025 | Slynd |
| Shield Therapeutics INC | $282.42 | 2022-2025 | Accrufer |
| Pfizer INC. | $191.20 | 2022-2025 | |
| Sage Therapeutics, LLC | $165.46 | 2024-2025 | Zurzuvae |
| Millicent US INC | $121.69 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Tesaro, INC. | $121.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.65 | 2019-2023 | |
| Astellas Pharma US INC | $114.84 | 2025 | Veozah |
| Lupin INC. | $81.48 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $66.73 | 2022-2025 | |
| Smith+Nephew, INC. | $51.78 | 2022-2024 | Pico 7 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.64 | 2020-2023 | Gardasil 9 |
| Mission Pharmacal Company | $51.04 | 2020-2021 | |
| Therapeuticsmd, INC. | $47.60 | 2019-2022 | |
| Avion Pharmaceuticals | $47.60 | 2022-2023 | Balcoltra |
| Medical Device Business Services, INC. | $47.23 | 2019 | |
| Lilly USA, LLC | $41.37 | 2025 | Mounjaro, Zepbound |
| Ethicon US, LLC | $35.91 | 2025 | Ethicon, Vistaseal, Evarrest |
| Coopersurgical, INC. | $35.45 | 2020-2025 | Paragard T 380a |
| Agile Therapeutics, INC. | $30.77 | 2021-2022 | |
| Dexcom, INC. | $28.79 | 2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $27.01 | 2024 | Thinprep 2000 Processor, Aptima |
| Medtronic, INC. | $25.82 | 2023 | V-Loc 180 |
| Evofem Biosciences, INC. | $24.79 | 2021 | |
| Biogen, INC. | $24.51 | 2025 | Zurzuvae |
| Meditrina | $23.86 | 2021 | |
| Amag Pharmaceuticals, INC. | $22.80 | 2019-2021 | |
| Daiichi Sankyo INC. | $22.62 | 2021 | |
| Organon LLC | $22.22 | 2022 | |
| Mylan Pharmaceuticals INC. | $20.99 | 2022 | |
| Optumhealth Care Solutions, LLC | $20.87 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Myovant Sciences INC. | $19.30 | 2022 | |
| Avanos Medical | $19.26 | 2021 | |
| Gynesonics, INC. | $16.37 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biohaven Pharmaceuticals, INC. | $15.40 | 2021 | |
| Ascend Therapeutics US, LLC | $14.10 | 2021 | |
| Boston Scientific Corporation | $13.91 | 2021 | |
| Innovation Technologies INC | $13.84 | 2024 | Irrisept |
| Allergan, INC. | $13.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yara Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.